Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics
- PMID: 38372457
- DOI: 10.1002/cpz1.957
Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics
Abstract
In neurodegenerative diseases like Alzheimer's disease (AD), endogenous proteins or peptides aggregate with themselves. These proteins may lose their function or aggregates and/or oligomers can obtain toxicity, causing injury or death to cells. Aggregation of two major proteins characterizes AD. Amyloid-β peptide (Aβ) is deposited in amyloid plaques within the extracellular space of the brain and Tau in so-called neurofibrillary tangles in neurons. Finding peptide ligands to halt protein aggregation is a promising therapeutical approach. Using mirror-image phage display with a commercially available, randomized 12-mer peptide library, we have selected D-amino acid peptides, which bind to the Tau protein and modulate its aggregation in vitro. Peptides can bind specifically and selectively to a target molecule, but natural L-amino acid peptides may have crucial disadvantages for in vivo applications, as they are sensitive to protease degradation and may elicit immune responses. One strategy to circumvent these disadvantages is the use of non-naturally occurring D-amino acid peptides as they exhibit increased protease resistance and generally do not activate the immune system. To perform mirror-image phage display, the target protein needs to be synthesized as D-amino acid version. If the target protein sequence is too long to be synthesized properly, smaller peptides derived from the full length protein can be used for the selection process. This also offers the possibility to influence the binding region of the selected D-peptides in the full-length target protein. Here we provide the protocols for mirror-image phage display selection on the PHF6* peptide of Tau, based on the commercially available Ph.D.™-12 Phage Display Peptide Library Kit, leading to D-peptides that also bind the full length Tau protein (Tau441), next to PHF6*. In addition, we provide protocols and data for the first characterization of those D-peptides that inhibit Tau aggregation in vitro. © 2024 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Mirror image phage display selection against D-PHF6* fibrils Support Protocol 1: Single phage ELISA Basic Protocol 2: Sequencing and D-peptide generation Basic Protocol 3: Thioflavin-T (ThT) test to control inhibition of Tau aggregation Support Protocol 2: Purification of full-length Tau protein Basic Protocol 4: ELISA to demonstrate the binding of the generated D-peptides to PHF6* and full-length Tau fibrils.
Keywords: D-enantiomer; mirror image phage display; peptide ligands; phage display.
© 2024 The Authors. Current Protocols published by Wiley Periodicals LLC.
Similar articles
-
Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.Chembiochem. 2021 Nov 3;22(21):3049-3059. doi: 10.1002/cbic.202100287. Epub 2021 Sep 12. Chembiochem. 2021. PMID: 34375027 Free PMC article.
-
Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.PLoS One. 2016 Dec 22;11(12):e0167432. doi: 10.1371/journal.pone.0167432. eCollection 2016. PLoS One. 2016. PMID: 28006031 Free PMC article.
-
Selection of a d-Enantiomeric Peptide Specifically Binding to PHF6 for Inhibiting Tau Aggregation in Transgenic Mice.ACS Chem Neurosci. 2020 Dec 16;11(24):4240-4253. doi: 10.1021/acschemneuro.0c00518. Epub 2020 Dec 7. ACS Chem Neurosci. 2020. PMID: 33284003
-
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease.Cell Mol Neurobiol. 2023 Apr;43(3):951-961. doi: 10.1007/s10571-022-01230-7. Epub 2022 May 21. Cell Mol Neurobiol. 2023. PMID: 35596819 Free PMC article. Review.
-
Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?J Biol Chem. 2018 Oct 5;293(40):15419-15428. doi: 10.1074/jbc.R118.003999. Epub 2018 Aug 24. J Biol Chem. 2018. PMID: 30143530 Free PMC article. Review.
Cited by
-
Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases.Molecules. 2024 Jun 25;29(13):3002. doi: 10.3390/molecules29133002. Molecules. 2024. PMID: 38998954 Free PMC article. Review.
-
Simple, rapid, and efficient purification of M13 phages: The Faj-elek method.PLoS One. 2025 Jun 6;20(6):e0325621. doi: 10.1371/journal.pone.0325621. eCollection 2025. PLoS One. 2025. PMID: 40478842 Free PMC article.
-
Therapeutic Peptides: Recent Advances in Discovery, Synthesis, and Clinical Translation.Int J Mol Sci. 2025 May 27;26(11):5131. doi: 10.3390/ijms26115131. Int J Mol Sci. 2025. PMID: 40507941 Free PMC article. Review.
-
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal Transduct Target Ther. 2025 Mar 5;10(1):74. doi: 10.1038/s41392-024-02107-5. Signal Transduct Target Ther. 2025. PMID: 40038239 Free PMC article. Review.
References
Literature Cited
References
-
- Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., Horn, A. H., Zweckstetter, M., Mandelkow, E., Sticht, H., & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential, designated ISAD1, inhibits aggregation of disease relevant pro-aggregate mutant Tau and prevents Tau toxicity in vitro. Alzheimer's Research & Therapy, 14, 15. https://doi.org/10.1186/s13195-022-00959-z
-
- Barghorn, S., Davies, P., & Mandelkow, E. (2004). Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on β-structure in the core domain †. Biochemistry, 43, 1694-1703. https://doi.org/10.1021/bi0357006
-
- Chalifour, R. J., McLaughlin, R. W., Lavoie, L., Morissette, C., Tremblay, N., Boulé, M., Sarazin, P., Stéa, D., Lacombe, D., Tremblay, P., & Gervais, F. (2003). Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. Journal of Biological Chemistry, 278, 34874-34881. https://doi.org/10.1074/jbc.M212694200
-
- Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., Horn, A. H. C., Sticht, H., Malhis, M. N., Will, N., Schuster, J., & Funke, S. A. (2016). Selection and characterization of Tau binding D-enantiomeric peptides with potential for therapy of Alzheimer disease. PLoS ONE, 11, e0167432. https://doi.org/10.1371/journal.pone.0167432
-
- Danho, W., Swistok, J., Khan, W., Chu, X. J., Cheung, A., Fry, D., Sun, H., Kurylko, G., Rumennik, L., Cefalu, J., Cefalu, G., & Nunn, P. (2009). Opportunities and challenges of developing peptide drugs in the pharmaceutical industry. Advances in Experimental Medicine and Biology, 611, 467-469.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous